Belite Bio, Inc (NasdaqCM: BLTE)
Health Care · Pharmaceuticals · US
$159.26
-2.17% today · +150.7% 1Y
Belite Bio, Inc (NasdaqCM: BLTE) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $6.40B and employs 41 people.
Over the last twelve months the share price has gained 150.7%, trading between 60.00 and 200.00.
Tweenvest scores Belite Bio, Inc across four factors: quality 20/100. Its strongest factor is quality.
BLTE price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $6.40B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -2.74
- Dividend yield
- —
- Beta (5Y)
- -1.22
- 52-week high
- $200.00
- 52-week low
- $60.00
- Avg volume (3M)
- —
- Shares outstanding
- 39.34M
- Employees
- 41
- Next earnings
- —
About Belite Bio, Inc
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
- ISIN
- US07782B1044
- Founded
- 2016
- Listed since
- Apr 29, 2022
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,226.58 | -0.57% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $271.58 | -0.57% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $153.68 | -1.77% |
| Roche Holding AGSWX: ROP | $371.62B | CHF369.70 | -1.10% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £122.92 | -1.47% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.35 | -0.77% |
Figures last refreshed Aug 18, 2026.